advanced urothelial carcinoma

You have access
Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy
TETSUYA SHINDO, KOHEI HASHIMOTO, ATSUSHI TAKAHASHI, SHINTARO MIYAMOTO, YASUHARU KUNISHIMA, SHUNSUKE SATO, FUMIMASA FUKUTA, YOSHIKI HIYAMA, AKIO TAKAYANAGI, RYUICHI KATO, ATSUSHI WANIFUCHI, YOHEI UEKI, MANABU OKADA, HIDEKI ADACHI, KO KOBAYASHI, TOSHIAKI TANAKA and NAOYA MASUMORI; on behalf of the Sapporo Medical University Urologic Oncology Consortium

Anticancer Research March 2024, 44 (3) 1271-1279; DOI: https://doi.org/10.21873/anticanres.16922
You have access
Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study
NOBUKI FURUBAYASHI, FUTOSHI MOROKUMA, TOSHIHISA TOMODA, YOSHIFUMI HORI, TAKAHITO NEGISHI, AKIHIRO MIURA, HIROKI KOMORI, KENTARO KUROIWA and MOTONOBU NAKAMURA

Anticancer Research March 2022, 42 (3) 1571-1577; DOI: https://doi.org/10.21873/anticanres.15631
You have access
Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma
MASAHIRO OGAWA, SHINYA YAMAMOTO, TORU INOUE, NOBORU NUMAO, TAKESHI YUASA, HITOSHI MASUDA, IWAO FUKUI and JUNJI YONESE

Anticancer Research March 2020, 40 (3) 1613-1618; DOI: https://doi.org/10.21873/anticanres.14109
You have access
High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma
HIROSHI YAEGASHI, KOUJI IZUMI, SUGURU KADOMOTO, RENATO NAITO, TOMOYUKI MAKINO, HIROAKI IWAMOTO, TAKAHIRO NOHARA, KAZUYOSHI SHIGEHARA, YOSHIFUMI KADONO and ATSUSHI MIZOKAMI

Anticancer Research January 2019, 39 (1) 375-380; DOI: https://doi.org/10.21873/anticanres.13122

Main menu

User menu

Search

advanced urothelial carcinoma